Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Reata Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
RETA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 25, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Reata Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA
September 30, 2021
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals's Return on Invested Capital Overview
↗
September 17, 2021
Benzinga Pro data, Reata Pharmaceuticals (NASDAQ:RETA) reported Q2 sales of $2.22 million. Earnings fell to a loss of $60.13 million, resulting in a 9.5% decrease from last...
Via
Benzinga
Why Reata Pharmaceuticals Stock Is Diving Today Despite Q2 Beats
↗
August 10, 2021
The FDA pours cold water on the company's better-than-expected quarter.
Via
The Motley Fool
Topics
Earnings
Reata's Stock Plunges After FDA Identifies Review Issues With Bardoxolone Methyl US Application
↗
August 10, 2021
Reata Pharmaceuticals Inc (NASDAQ: RETA) issued an update regarding its Bardoxolone Methyl application for chronic kidney disease (CKD) caused by Alport syndrome....
Via
Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
↗
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
85 Biggest Movers From Yesterday
↗
August 11, 2021
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX...
Via
Benzinga
54 Stocks Moving In Tuesday's Mid-Day Session
↗
August 10, 2021
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
August 10, 2021
Gainers Arcturus Therapeutics (NASDAQ:ARCT) shares rose 25.93% to $60.75 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5...
Via
Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
↗
August 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...
Via
Benzinga
28 Stocks Moving in Tuesday's Pre-Market Session
↗
August 10, 2021
Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares rose 38.6% to $66.88 in pre-market trading after the company reported better-than-expected Q2 earnings and also...
Via
Benzinga
Reata Pharmaceuticals, inc (RETA) Q2 2021 Earnings Call Transcript
↗
August 10, 2021
RETA earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
8 Stocks Moving In Monday's After-Hours Session
↗
August 09, 2021
Gainers Kansas City Southern (NYSE: KSU) shares are trading higher following a report suggesting Canadian Pacific plans a new higher bid for the company, near $300 per share....
Via
Benzinga
Reata Pharmaceuticals: Q2 Earnings Insights
↗
August 09, 2021
Shares of Reata Pharmaceuticals (NASDAQ:RETA) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 7.32%...
Via
Benzinga
Reata Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs
August 09, 2021
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals, Inc. to Report Second Quarter 2021 Financial Results and Provide an Update on Development Programs on August 9, 2021
August 02, 2021
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Biotech Stocks Cruise Through The Volatility
↗
May 25, 2021
The XLV Healthcare Select SPDR is up 10% YTD.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2021
↗
May 24, 2021
Upgrades Seaport Global upgraded the previous rating for Public Service Enterprise Group Inc (NYSE:PEG) from Neutral to Buy. Public Service Enterprise earned $1.28 in the...
Via
Benzinga
Earnings Scheduled For August 9, 2021
↗
August 09, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...
Via
Benzinga
Unusual Options Activity Insight: Reata Pharmaceuticals
↗
May 21, 2021
On Friday, shares of Reata Pharmaceuticals (NASDAQ:RETA) saw unusual options activity. After the option alert, the stock price moved up to $111.92. Sentiment: BULLISH Option...
Via
Benzinga
50 Biggest Movers From Yesterday
↗
May 20, 2021
Gainers MoSys, Inc. (NASDAQ: MOSY) shares jumped 44.1% to settle at $5.46 on Wednesday. Lianluo Smart Limited (NASDAQ: LLIT) gained 24.6% to settle at $9.22. Reata...
Via
Benzinga
Why Reata Pharmaceuticals Stock Is Skyrocketing Today
↗
May 19, 2021
The company might soon be taking a very big step toward FDA approval of an important pipeline drug.
Via
The Motley Fool
Mid-Afternoon Market Update: Dow Falls 1%; Iovance Biotherapeutics Shares Plunge
↗
May 19, 2021
Toward the end of trading Wednesday, the Dow traded down 1.08% to 33,693.98 while the NASDAQ fell 0.66% to 13,215.41. The S&P also fell, dropping 0.94% to 4,088.99. The U.S....
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
May 19, 2021
Gainers Lianluo Smart (NASDAQ:LLIT) stock rose 35.13% to $10.0 during Wednesday's regular session. Lianluo Smart's stock is trading at a volume of 4.6 million...
Via
Benzinga
Mid-Day Market Update: Crude Oil Down 5%; Reata Pharmaceuticals Shares Jump
↗
May 19, 2021
Midway through trading Wednesday, the Dow traded down 1.32% to 33,610.27 while the NASDAQ fell 0.89% to 13,184.68. The S&P also fell, dropping 1.20% to 4,078.44. The U.S. has...
Via
Benzinga
Topics
Stocks
35 Stocks Moving In Wednesday's Mid-Day Session
↗
May 19, 2021
Gainers Advaxis, Inc. (NASDAQ: ADXS) shares jumped 43.1% to $0.6943 after jumping over 14% on Tuesday. MoSys, Inc. (NASDAQ: MOSY) shares gained 32% to $5.00. Reata...
Via
Benzinga
Mid-Morning Market Update: Markets Open Lower; Target Profit Beats Estimates
↗
May 19, 2021
Following the market opening Wednesday, the Dow traded down 1.47% to 33,559.29 while the NASDAQ fell 1.29% to 13,131.99. The S&P also fell, dropping 1.42% to 4,069.40. The U.S...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
May 19, 2021
Gainers Advaxis (NASDAQ:ADXS) shares increased by 27.34% to $0.62 during Wednesday's pre-market session. The company's market cap stands at $85.2 million. Lixte...
Via
Benzinga
The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics
↗
May 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) Alexion Pharmaceuticals, Inc...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
↗
May 14, 2021
Before 10 a.m. ET on Friday, 24 stocks hit new 52-week lows. Noteworthy Mentions: The largest company in terms of market cap to set a new 52-week low was Canadian...
Via
Benzinga
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
↗
May 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.